References
- 1. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062-2076.10.1016/j.jacc.2010.02.02520447528
- 2. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881-1889.10.1016/j.jacc.2011.03.07222018299
- 3. Ndumele CE, Matsushita K, Sang Y, et al. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016;133:631-638.10.1161/CIRCULATIONAHA.115.017298475886326746175
- 4. Wang YC, Yu CC, Chiu FC, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail. 2013;19:163-168.10.1016/j.cardfail.2013.01.01023482076
- 5. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63:158-166.10.1016/j.jacc.2013.07.08724076531
- 6. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2:65-72.10.1016/j.jchf.2013.10.00524622120
- 7. Zhu ZD, Sun T. Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients. Genet Mol Res. 2015;14:2225-2233.10.4238/2015.March.27.825867369
- 8. Mueller T, Leitner I, Egger M. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta. 2015;445:155-160.10.1016/j.cca.2015.03.03325850080
- 9. Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2016;18(1):81-88.10.1002/ejhf.43126497848
- 10. Scharnagl H, Kleber ME, Genser B, et al. Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC study. Int J Cardiol. 2014;174:96-105.10.1016/j.ijcard.2014.03.168404519024746542
- 11. Gedikli O, Kiris A, Hosoglu Y, et al. Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not troponin T in patients with chronic heart failure. Med Princ Pract. 2015;24:42-46.10.1159/000368717558819625402608
- 12. Schiele F, Meneveau N, Seronde MF, et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J. 2010;31:290-297.10.1093/eurheartj/ehp27319578164
- 13. Parrinello CM, Lutsey PL, Ballantyne CM, et al. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015;170:380-389.10.1016/j.ahj.2015.04.017454885726299237
- 14. Aulin J, Siegbahn A2, Hijazi Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015;170:1151-1160.10.1016/j.ahj.2015.09.01826678637
- 15. Canada JM, Fronk DT, Cei LF, et al. Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure. Am J Cardiol. 2016;117:116-120.10.1016/j.amjcard.2015.10.02026546248
- 16. Kozdağ G, Ertaş G, Kiliç T, et al. Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. Med Sci Monit. 2010;16:CR156-161.
- 17. Schmalgemeier H, Bitter T, Fischbach T, et al. C-reactive protein is elevated in heart failure patients with central sleep apnea and Cheyne-Stokes respiration. Respiration. 2014;87:113-120.10.1159/00035111523988380
- 18. Ataoğlu HE, Yilmaz F, Uzunhasan I, et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res. 2010;38:52-61.10.1177/14732300100380010620233513
- 19. Kelly D, Khan SQ, Dhillon O, et al. Procalcitonin as a prognostic marker in patients with acute myocardial infarction. Biomarkers. 2010;15:325-331.10.3109/1354750100367508420214413
- 20. Sinning CR, Sinning JM, Schulz A, et al.; Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J. 2011;75:1184-1191.10.1253/circj.CJ-10-0638
- 21. Schiopu A, Hedblad B, Engström G, et al. Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J Intern Med. 2012;272:484-491.10.1111/j.1365-2796.2012.02548.x22530956
- 22. Canbay A, Celebi OO, Celebi S, et al. Procalcitonin: a marker of heart failure. Acta Cardiol. 2015;70(4):473-478.10.1080/AC.70.4.309689626455251
- 23. Loncar G, Tscholl V, Tahirovic E, et al. Should procalcitonin be measured routinely in acute decompensated heart failure. Biomark Med. 2015;9:651-659.10.2217/bmm.15.2926174839
- 24. Wang W, Zhang X, Ge N, et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit Care. 2014;18:R4.10.1186/cc13181405610524393388
- 25. Alba GA, Truong QA, Gaggin HK, et al. Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. Am J Med. 2016;129:96-104.10.1016/j.amjmed.2015.06.03726169892
- 26. Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol. 2014;175:464-472.10.1016/j.ijcard.2014.06.02225005339
- 27. Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718-725.10.1093/eurjhf/hfr04721551163
- 28. Pascual-Figal DA, Casas T, Ordonez-Llanos J, et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J. 2012;163:1002-1010.10.1016/j.ahj.2012.03.01522709753
- 29. Grodin JL, Neale S, Wu Y, et al. Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure. Am J Med. 2015;128:276-282.10.1016/j.amjmed.2014.09.029434072225447612
- 30. Haaf P, Reichlin T, Twerenbold R. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J. 2014;35:365-375.10.1093/eurheartj/eht21823821402
- 31. Hendgen-Cotta UB, Kelm M, Rassaf T. Myoglobin functions in the heart. Free Radic Biol Med. 2014;73:252-259.10.1016/j.freeradbiomed.2014.05.00524859377
- 32. Wang Q, Liu F, Yang X, et al. Sensitive point-of-care monitoring of cardiac biomarker myoglobin using aptamer and ubiquitous personal glucose meter. Biosens Bioelectron. 2015;64:161-164.10.1016/j.bios.2014.08.07925216451
- 33. Lee HY, Choi JS, Guruprasath P, et al. An Electrochemical Biosensor Based on a Myoglobin-specific Binding Peptide for Early Diagnosis of Acute Myocardial Infarction. Anal Sci. 2015;31:699-704.10.2116/analsci.31.69926165294
- 34. Li X, Luo R, Jiang R, et al. The prognostic use of serum concentrations of cardiac troponin-I, CK-MB and myoglobin in patients with idiopathic dilated cardiomyopathy. Heart Lung. 2014;43:219-224.10.1016/j.hrtlng.2014.03.00124794782
- 35. Polat V, Bozcali E, Uygun T, et al. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol. 2016;71:191-197.10.1080/AC.71.2.3141849
- 36. Schindler EI, Szymanski JJ, Hock KG, et al. Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults. Clin Chem. 2016;62:360-366.10.1373/clinchem.2015.24655326546635
- 37. Song X, Qian X, Shen M, et al. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta. 2015;1853:513-521.10.1016/j.bbamcr.2014.12.00125489662
- 38. Yu X, Sun Y, Zhao Y, et al. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Int Heart J. 2015;56:314-318.10.1536/ihj.14-30425902879
- 39. Lai KB, Sanderson JE, Izzat MB, et al. Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. Int J Cardiol. 2015;199:79-83.10.1016/j.ijcard.2015.07.04326188824
- 40. Devaux Y, Vausort M, McCann GP, et al. A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction. PLoS One. 2013;8:e70644.10.1371/journal.pone.0070644374277623967079
- 41. Kumarswamy R, Bauters C, Volkmann I, et al. Brief UltraRapid Communication (Clinical Track) Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure. Circulation Research. 2014;114:1569-1575.10.1161/CIRCRESAHA.114.30391524663402
- 42. Gu YL, Voors AA, Zijlstra F, et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol. 2011;100:1069-1076.10.1007/s00392-011-0343-y322282721766239
- 43. Meune C, Zuily S, Wahbi K, et al. Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: a pilot study. Arch Cardiovasc Dis. 2011;104:4-10.10.1016/j.acvd.2010.11.00221276572
- 44. Pozsonyi Z, Förhécz Z, Gombos T. Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. Heart Lung Circ. 2015;24:359-367.10.1016/j.hlc.2014.10.00825618448
- 45. Vizzardi E, Bonadei I, Sciatti E, et al. Quantitative analysis of right ventricular (RV) function with echocardiography in chronic heart failure with no or mild RV dysfunction: comparison with cardiac magnetic resonance imaging. J Ultrasound Med. 2015;34:247-255.10.7863/ultra.34.2.24725614398
- 46. Pellicori P, Zhang J, Lukaschuk E, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J. 2015;36:733-742.10.1093/eurheartj/ehu40525336215
- 47. Won E, Donnino R, Srichai MB, et al. Diagnostic Accuracy of Cardiac Magnetic Resonance Imaging in the Evaluation of Newly Diagnosed Heart Failure With Reduced Left Ventricular Ejection Fraction. Am J Cardiol. 2015;116:1082-1087.10.1016/j.amjcard.2015.06.032456794026251006
- 48. Bellevre D, Manrique A, Legallois D, et al. First determination of the heart-to-mediastinum ratio using cardiac dual isotope (123I-MIBG/99mTc-tetrofosmin) CZT imaging in patients with heart failure: the ADRECARD study. Eur J Nucl Med Mol Imaging. 2015;42:1912-1919.10.1007/s00259-015-3141-326227533
- 49. Narula J, Gerson M, Thomas GS, et al. 123I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study. J Nucl Med. 2015;56:1011-1018.10.2967/jnumed.115.15640626069309
- 50. Rommel KP, von Roeder M, Latuscynski K, et al. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2016;67:1815-1825.10.1016/j.jacc.2016.02.01827081022